Glenmark gets FDA nod for Raloxifene Hydrochloride Tablets

Glenmark Pharmaceuticals receives ANDA approval for Raloxifene Hydrochloride Tablets USP, 60 mg


Glenmark's drug is the therapeutic equivalent to Evista Tablets, 60 mg, of Eli Lilly and Company

Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Raloxifene Hydrochloride Tablets USP, 60 mg, the therapeutic equivalent to the reference listed drug product, Evista Tablets, 60 mg, of Eli Lilly and Company.

According to IMS Health sales data for the 12 month period ending January 2016, the Evista Market achieved annual sales of approximately $336.5 million.

"Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride. Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride," Glenmark said in a warning, statement.

"Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke," the company added.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email